KR20230035346A - SARS-CoV-2를 표적으로 하는 항원 결합 분자 - Google Patents

SARS-CoV-2를 표적으로 하는 항원 결합 분자 Download PDF

Info

Publication number
KR20230035346A
KR20230035346A KR1020237003773A KR20237003773A KR20230035346A KR 20230035346 A KR20230035346 A KR 20230035346A KR 1020237003773 A KR1020237003773 A KR 1020237003773A KR 20237003773 A KR20237003773 A KR 20237003773A KR 20230035346 A KR20230035346 A KR 20230035346A
Authority
KR
South Korea
Prior art keywords
seq
polypeptide
ser
thr
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237003773A
Other languages
English (en)
Korean (ko)
Inventor
게보그 그리고리안
존 인그라함
척 룬 령
로스 스티븐 페더먼
로빈 제프리 그린
빈센트 쉬에
크레이그 오웬 맥켄지
Original Assignee
플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 filed Critical 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨
Publication of KR20230035346A publication Critical patent/KR20230035346A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020237003773A 2020-07-06 2021-07-06 SARS-CoV-2를 표적으로 하는 항원 결합 분자 Pending KR20230035346A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063048588P 2020-07-06 2020-07-06
US63/048,588 2020-07-06
US202063070038P 2020-08-25 2020-08-25
US63/070,038 2020-08-25
PCT/US2021/040533 WO2022010912A1 (en) 2020-07-06 2021-07-06 Antigen binding molecules targeting sars-cov-2

Publications (1)

Publication Number Publication Date
KR20230035346A true KR20230035346A (ko) 2023-03-13

Family

ID=77155889

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237003773A Pending KR20230035346A (ko) 2020-07-06 2021-07-06 SARS-CoV-2를 표적으로 하는 항원 결합 분자

Country Status (8)

Country Link
US (1) US12473560B2 (https=)
EP (1) EP4175984A1 (https=)
JP (1) JP2023534922A (https=)
KR (1) KR20230035346A (https=)
AU (1) AU2021305067A1 (https=)
CA (1) CA3183373A1 (https=)
IL (1) IL299631A (https=)
WO (1) WO2022010912A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL299631A (en) 2020-07-06 2023-03-01 Flagship Pioneering Innovations Vi Llc Antigen binding molecules targeting sars-cov-2
CA3183367A1 (en) 2020-07-06 2022-01-13 Gevorg GRIGORYAN Antigen binding molecules targeting sars-cov-2
KR20230058434A (ko) 2020-08-26 2023-05-03 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 SARS-CoV-2를 표적으로 하는 항원 결합 분자
AU2023265164A1 (en) 2022-05-06 2024-11-21 Generate Biomedicines, Inc. Antigen binding molecules targeting sars-cov-2
JP2025537301A (ja) 2022-11-13 2025-11-14 ジェネレイト バイオメディシンズ， インコーポレイテッド Ｓａｒｓ－ｃｏｖ－２を標的とする抗原結合分子

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2531684C (en) 2003-07-22 2014-03-11 Crucell Holland B.V. Binding molecules against sars-coronavirus and uses thereof
CA2548942C (en) * 2003-12-05 2013-10-15 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health Anti-sars monoclonal antibodies
EP1812067B1 (en) 2004-11-11 2012-03-21 Crucell Holland B.V. Compositions against sars-coronavirus and uses thereof
DK1817340T3 (da) 2004-11-12 2012-08-13 Xencor Inc Fc-varianter med ændret binding til fcrn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
RU2529951C2 (ru) 2007-12-26 2014-10-10 Ксенкор, Инк. ВАРИАНТЫ Fc С ИЗМЕНЕННЫМ СВЯЗЫВАНИЕМ C FcRn
PT3031913T (pt) 2013-08-09 2019-05-31 Astellas Pharma Inc Novo anticorpo anti-receptor de tslp humana
CA2962731A1 (en) 2014-10-01 2016-04-07 Medimmune Limited Binding proteins specific for lox1 and uses thereof
CR20180365A (es) 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
JP7695698B2 (ja) 2019-01-14 2025-06-19 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 細胞内部移行をモジュレートするための組成物および方法
AR120698A1 (es) 2019-12-09 2022-03-09 Ablynx Nv Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp
JP2023512684A (ja) 2020-02-03 2023-03-28 ヴィア・バイオテクノロジー・インコーポレイテッド Ｓａｒｓ－ｃｏｖ－２に対する抗体およびそれを使用する方法
WO2021156490A2 (en) 2020-02-06 2021-08-12 Vib Vzw Corona virus binders
SG11202110145SA (en) 2020-02-26 2021-10-28 Vir Biotechnology Inc Antibodies against sars-cov-2 and methods of using the same
CN115515976A (zh) 2020-03-19 2022-12-23 帝国理工学院创新有限公司 冠状病毒抗体
US11028167B1 (en) * 2020-03-23 2021-06-08 Centivax, Inc. Anti-SARS-Cov-2 antibodies derived from 3bgf
CR20220552A (es) 2020-04-02 2023-01-17 Regeneron Pharma Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno
WO2021203053A1 (en) 2020-04-03 2021-10-07 Vir Biotechnology, Inc. Immunotherapy targeting a conserved region in sars coronaviruses
US20230348571A1 (en) 2020-04-06 2023-11-02 Vanderbilt University Cross-reactive coronavirus antibodies and uses thereof
TW202204397A (zh) 2020-04-10 2022-02-01 美商亞得捷歐治療公司 對冠狀病毒s蛋白質具特異性之化合物及其用途
JP2023523549A (ja) 2020-04-14 2023-06-06 ヴィア・バイオテクノロジー・インコーポレイテッド ＳＡＲＳ－ＣｏＶ－２に対する抗体およびそれを使用する方法
CN115461364B (zh) 2020-04-28 2025-12-16 北京大学 一种抗新型冠状病毒的单克隆抗体及其应用
MX2022013886A (es) 2020-05-08 2022-11-30 Vir Biotechnology Inc Anticuerpos contra coronavirus de tipo 2 causante del sindrome respiratorio agudo severo (sars-cov-2).
WO2021247925A1 (en) 2020-06-03 2021-12-09 Vir Biotechnology, Inc. Structure-guided immunotherapy against sars-cov-2
CA3183367A1 (en) 2020-07-06 2022-01-13 Gevorg GRIGORYAN Antigen binding molecules targeting sars-cov-2
IL299631A (en) 2020-07-06 2023-03-01 Flagship Pioneering Innovations Vi Llc Antigen binding molecules targeting sars-cov-2
WO2022015573A2 (en) 2020-07-13 2022-01-20 President And Fellows Of Harvard College Sars-cov-2 antigen-binding proteins and uses thereof
EP4188951A4 (en) 2020-07-27 2024-08-28 IGM Biosciences, Inc. Multimeric coronavirus binding molecules and uses thereof
WO2022046888A1 (en) 2020-08-25 2022-03-03 Target Discovery Merger Sub II, LLC Sars-cov-2 associated antibody compositions and methods of use
KR20230058434A (ko) 2020-08-26 2023-05-03 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 SARS-CoV-2를 표적으로 하는 항원 결합 분자
JP2024502046A (ja) 2020-12-29 2024-01-17 バル－チャム，リミティド パートナーシップ Ｃｏｖｉｄ－１９に対する中和モノクローナル抗体
WO2022159685A2 (en) 2021-01-22 2022-07-28 Vanderbilt University Sars-cov-2 coronavirus antibodies and uses thereof
WO2022204202A1 (en) 2021-03-23 2022-09-29 Vir Biotechnology, Inc. Antibodies that bind to multiple sarbecoviruses
CA3218489A1 (en) 2021-05-24 2022-12-01 Vir Biotechnology, Inc. Engineered polypeptides
US20240270797A1 (en) 2021-06-23 2024-08-15 Cz Biohub Sf, Llc Coronavirus neutralizing compositions and associated methods
TW202315895A (zh) 2021-08-27 2023-04-16 瑞士商休曼生物醫藥股份公司 經工程化的組成物
EP4147716A1 (en) 2021-09-10 2023-03-15 Samatva Research Corporation Anti-virus moiety immobilised in a matrix
AU2023265164A1 (en) 2022-05-06 2024-11-21 Generate Biomedicines, Inc. Antigen binding molecules targeting sars-cov-2

Also Published As

Publication number Publication date
IL299631A (en) 2023-03-01
EP4175984A1 (en) 2023-05-10
JP2023534922A (ja) 2023-08-15
WO2022010912A1 (en) 2022-01-13
US20230279081A1 (en) 2023-09-07
CA3183373A1 (en) 2022-01-13
US12473560B2 (en) 2025-11-18
AU2021305067A1 (en) 2023-02-09

Similar Documents

Publication Publication Date Title
TWI847020B (zh) 抗冠狀病毒抗體及使用方法
US11987616B2 (en) Antigen binding molecules targeting SARS-CoV-2
KR20230035346A (ko) SARS-CoV-2를 표적으로 하는 항원 결합 분자
US11981725B2 (en) Antigen binding molecules targeting SARS-CoV-2
US20250145690A1 (en) Human monoclonal antibodies that broadly target coronaviruses
KR20170138494A (ko) 항-ｔｙｒ０３ 항체 및 이의 용도
EP3204414B1 (en) Novel anti-nodal antibodies and methods of using same
TWI832013B (zh) 一種抗pd-l1抗原結合蛋白及其應用
CN116897053A (zh) 含抗tslp抗体的药物组合物
KR102748987B1 (ko) 사스-코로나바이러스-2에 특이적으로 결합하는 항체 및 그의 용도
KR20220155338A (ko) 뮤신 17에 대한 항체 및 이의 용도
US20230287090A1 (en) USE OF SARS-CoV-2 RECEPTOR BINDING MOTIF (RBM)-REACTIVE MONOCLONAL ANTIBODIES TO TREAT COVID-19
US20260092100A1 (en) Antibodies against metapneumovirus fusion (f) protein and uses thereof
WO2013162748A1 (en) Anti-tumor endothelial marker-1 (tem1) antibody variants and uses thereof
US20250270346A1 (en) Efficacious anti-cd26 antibody biomarker
US11359007B2 (en) Anti-SARS-CoV-2 neutralizing antibodies
CN116547005A (zh) 靶向SARS-CoV-2的抗原结合分子
CN116635410A (zh) 靶向SARS-CoV-2的抗原结合分子
CN119546636A (zh) FcRn-结合多肽及其用途
CN119546630A (zh) 特异性结合rsv的抗体

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000